Associated Papers
[Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T et al.
Mikrobiyoloji Bulteni, 2017
No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.
Hoffmann L et al.
Bba Clinical, 2015
Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
Nguyen LT et al.
Antiviral Therapy, 2015
Select a paper to view details